Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
65 hedge funds and large institutions have $817M invested in Akcea Therapeutics Inc in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 9 closing their positions.
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
47% more capital inflows, than outflows
Capital inflows: $53M | Capital outflows: $36.2M
16% more funds holding
Funds holding: 56 → 65 (+9)
0.58% more ownership
Funds ownership: 26.64% → 27.22% (+0.58%)
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
68% less call options, than puts
Call options by funds: $13.4M | Put options by funds: $41.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$22.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.2M |
| 3 |
SC
Sculptor Capital
New York
|
+$3.24M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$25.1M |
| 2 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$3.1M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$2.95M |
| 4 |
Millennium Management
New York
|
-$1.52M |
| 5 |
Goldman Sachs
New York
|
-$523K |
AKCA Hedge Fund Activity: Q3 2018 in Review
65 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q3 2018, worth a combined $817M — up 51% from $541M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AKCA positions and 9 closed out — a net gain of 9 holders — while 18 added to existing stakes and 19 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $22.8M. The largest seller was Wellington Management Group, cutting an estimated $25.1M.
- 65 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q3 2018, up from 56 in Q2 2018.
- Funds reported $817M of Akcea Therapeutics Inc stock for Q3 2018, up 51% quarter-over-quarter.
- 18 funds opened new Akcea Therapeutics Inc positions in Q3 2018 and 9 closed out, a net change of +9 holders.
- The largest Akcea Therapeutics Inc buyer in Q3 2018 was EcoR1 Capital, an estimated $22.8M added.
- The largest Akcea Therapeutics Inc seller in Q3 2018 was Wellington Management Group, an estimated $25.1M sold.
Based on aggregated 13F filings for Q3 2018.